Waldencast plc Stock Price, News & Analysis

Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its upcoming earnings release and conference call schedule for Q4/FY2024 and the first three quarters of FY2025. Key dates include:

- Q4/FY2024: Earnings release on March 18, 2025, after market close; Conference call on March 19, 2025, at 8:30am ET
- Q1 2025: Earnings release on May 13, 2025, after market close; Conference call on May 14, 2025, at 8:30am ET
- Q2 2025: Earnings release on August 18, 2025, after market close; Conference call on August 19, 2025, at 8:30am ET
- Q3 2025: Earnings release on November 11, 2025, after market close; Conference call on November 12, 2025, at 8:30am ET

All webcasts and presentations will be available on the company's Investor Relations website approximately two weeks before each event.

Waldencast (NASDAQ: WALD) announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress in Paris from January 30 to February 1, 2025. The event brings together industry leaders in dermatology, plastic surgery, and aging science.

CEO Michel Brousset will join a capital markets roundtable discussing medical grade skincare and the beauty industry's future. Dr. Suzan Obagi, Chief Medical Director at Obagi Medical, will deliver two presentations: one on pairing skincare with procedures and minimizing energy-based device complications, and another symposium focused on hyperpigmentation.

Milk Makeup, part of Waldencast plc (NASDAQ: WALD), has announced its expansion into Ulta Beauty, the nation's largest beauty retailer. Starting spring 2025, Milk Makeup's products will be available in 600+ Ulta Beauty stores nationwide and on Ulta.com.

The brand, recognized as a top 20 EMV makeup brand globally with 75% EMV growth last year, will offer its full assortment of 150+ products, priced between $20-$52. The partnership includes popular items like the 13x award-winning Hydro Grip Primer and Cooling Water Jelly Tints. The brand will be featured through an eye-catching display highlighting its 'Live Your Look' ethos and will be part of Ulta Beauty's Conscious Beauty initiative.

This expansion marks a significant milestone for Milk Makeup since its 2016 debut and aligns with both companies' shared values of inclusivity, community, and creative self-expression.

Waldencast (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its participation in the upcoming ICR Conference 2025 at The Grande Lakes Orlando in Florida. Michel Brousset, Founder and CEO, and Manuel Manfredi, CFO, will deliver a presentation on January 13, 2025, at 9:30 a.m. EST. The presentation will be accessible live and available for replay on the company's Investor Relations webpage at www.ir.waldencast.com.

Waldencast reported strong Q3 2024 results with net revenue of $70.2 million, representing a 34.6% comparable growth. Obagi Medical achieved 45.5% growth while Milk Makeup grew 23.5% compared to Q3 2023. Adjusted EBITDA reached $11.4 million, up 134.0% year-over-year, with margin expanding to 16.3%. The company maintained its guidance for full-year comparable net revenue growth above 25.7% with mid-teens adjusted EBITDA margin. As of September 30, 2024, the company had $17.6 million in cash and $154.0 million in net debt.

Waldencast plc (NASDAQ: WALD) has scheduled its Third Quarter Fiscal 2024 earnings conference call and webcast for November 21, 2024, at 8:30am ET. The company will release its financial results on November 20, 2024, after the U.S. market closes. Investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international calls. The webcast will include a slide presentation and can be accessed at the company's investor relations website, with a replay available for 90 days.

Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced three new appointments to its Board of Directors: Hind Sebti, Kelly Brookie, and Roberto Thompson, effective September 26, 2024. These additions bring extensive experience in beauty, finance, and consumer products sectors. The company's Annual General Meeting is scheduled for October 28, 2024, where shareholders will vote on the renewal of Class I and II directors.

Hind Sebti, co-founder and Chief Growth Officer of Waldencast, brings over 20 years of beauty industry experience. Kelly Brookie, a retired Deloitte Audit Partner, will serve on the Audit and Governance Committee. Roberto Thompson, a former co-founder of 3G Capital, will join the Finance Committee. The Board will now include 11 members, reflecting the company's commitment to maintaining a strong and diverse leadership team.

Obagi Medical, a subsidiary of Waldencast plc (NASDAQ: WALD), has launched two new skincare products: ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate. These innovations expand the ELASTIDERM® collection, offering transformative results for skin appearance and texture.

The Lift Up & Sculpt Facial Moisturizer, priced at $135, uses the patented Bi-Mineral Contour Complex™ to support skin elasticity and target aging signs. It also includes Polyglutamic Acid for intense hydration. The Advanced Filler Concentrate, priced at $115, contains Acetyl Hexapeptide-1 to re-plump and smooth wrinkles.

Both products will be available through professional channels and on Obagi.com from September 23rd. They are designed to complement in-office procedures and offer effective alternatives for those seeking anti-aging solutions outside clinical settings.

Waldencast plc (NASDAQ: WALD) reported strong Q2 2024 financial results, with net revenue of $63.3 million, up 25.7% in comparable growth. Key highlights include:

- Obagi Medical: 30.9% comparable growth
- Milk Makeup: 20.0% comparable growth
- Adjusted EBITDA of $6.3 million, up 64.5% vs Q2 2023
- Adjusted Gross Profit Margin improved to 75.0%, up 650 basis points

The company expects to further accelerate H2 2024 net revenue growth above Q2 rates and achieve a mid-teens Adjusted EBITDA Margin for the full year. Both brands saw strong community engagement and successful product launches, positioning them for continued growth in H2 2024.